Lack of Benefit of Intravenous Synthetic Human Secretin in the Treatment of Autism

Journal of Autism and Developmental Disorders

Volumn 32, Issue 6, 2002, Pages 545-551

  Molloy, Cynthia A ^a,b   Manning Courtney, Patricia ^a   Swayne, Susan ^a   Bean, Judy ^a   Brown, Jennifer M ^b   Murray, Donna S ^a,c   Kinsman, Anne M ^a   Brasington, Mark ^b   Ulrich II, Charles D ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Autism; Clinical trial; Human synthetic secretin

Indexed keywords

SECRETIN; GASTROINTESTINAL AGENT;

ADOLESCENT; ARTICLE; AUTISM; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LANGUAGE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; INTRAVENOUS DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADOLESCENT; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SECRETIN; TREATMENT OUTCOME;

EID: 0037504305     PISSN: 01623257     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021202930206     Document Type: Article

References (23)

1. Aman, M., & Singh, M. (1994). Abberrant Behavior Checklist-Community. East Aurora, NY: Slosson Educational Publications, Inc.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed). Washington, D. C.: Author.
3. Bristol-Power, M. M., & Spinella, G. (1999). Research on screening and diagnosis in autism: A work in progress. Journal of Autism and Developmental Disorders, 29(6), 435-438.
4. Bryson, S. E. (1996). Brief report: Epidemiology of autism. Journal of Autism and Developmental Disorders, 26, 165-167.
5. Chez, M. G., Buchanan, C. P., Bagan, B. T., Hammer, M. S., McCarthy, K. S., Ovrutskaya, I., et al. (2000). Secretin and autism: A two-part clinical investigation [In Process Citation]. Journal of Autism and Developmental Disorders, 30(2), 87-94.
6. Coniglio, S. J., Lewis, J. D., Lang, C., Burns, T. G., Subhani-Siddique, R., Weintraub, A., et al. (2001). A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. Journal of Pediatrics, 138(5), 649-655.
7. Dunn, L., & Dunn, L. (1997). Peabody Picture Vocabulary Test. Circle Pines, MN: American Guidance Service.
8. Dunn-Geier, J., Ho, H. H., Auersperg, E., Doyle, D., Eaves, L., Matsuba, C., et al. (2000). Effect of secretin on children with autism: A randomized controlled trial. [In Process Citation]. Developmental Medicine and Child Neurology, 42(12), 796-802.
9. Fremeau, R. T., Jr., Korman, L. Y., & Moody, T. W. (1986). Secretin stimulates cyclic AMP formation in the rat brain. Journal of Neurochemistry, 46(6), 1947-1955.
10. Gilliam, J. E. (1995). Gilliam Autism Rating Scale. Austin, TX: Pro-ed.
11. Hammill, D., Pearson, N., & Voress, J. (1993). Developmental Test of Visual Perception (2nd ed.). Austin, TX: Pro-Ed.
12. Horvath, K., Papadimitriou, J. C., Rabsztyn, A., Drachenberg, C., & Tildon, J. T. (1999). Gastrointestinal abnormalities in children with autistic disorder [see comments]. Journal of Pediatrics, 135(5), 559-563.
13. Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Journal of the Association for Academic Minority Physicians, 9(1), 9-15.
14. Krug, D., Arick, J., & Almond, P. (1980). Autism Behavior Checklist. Austin, TX: Pro-Ed.
15. Mullen, E. M. (1995). Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service.
16. Owley, T., Steele, M., Corsello, C., Risi, S., McKaig, K., Lord, C., et al. (1999). A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape General Medicine/journal/1999/v01.n10.
17. Sandler, A. D., Sutton, K. A., DeWeese, J., Girardi, M. A., Sheppard, V., & Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder [see comments]. New England Journal of Medicine, 341(24), 1801-1806.
18. Schopler, E. (1988). The Childhood Autism Rating Scale. Los Angeles, CA: Western Psychological Services.
19. Shipley, K., & McAfee, J. (1992). Assessment in Speech-Language Pathology. San Diego, CA: Singular Publishing Group.
20. Somogyi, L., Cintron, M., & Toskes, P. P. (1999). Synthetic human secretin compared to synthetic porcine secretin in pancreatic function testing [abstract]. Pancreas, 19, 439.
21. Somogyi, L., Cintron, M., & Toskes, P. P. (2000). Synthetic porcine secretin is highly accurate in pancreatic function testing in individuals with chronic pancreatitis. Pancreas, 21(3), 262-265.
22. Stutsman, R. (1981). Merrill-Pahner Scale of Mental Tests. Wood Dale, IL: Stoelting Co.
23. Ulrich, C. D., II, Holtmann, M., & Miller, L. J. (1998). Secretin and vasoactive intestinal peptide receptors: Members of a unique family of G protein-coupled receptors. Gastroenterology, 114(2), 382-397.